Latest Breaking News On - ப்ரைமரீ இறுதிப்புள்ளி - Page 6 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Valneva and Pfizer Announce Initiation of Phase 2 Study for Lyme Disease Vaccine Candidate VALNEVAMarch 8, 2021 GMT The Phase 2 study will include both adult and pediatric subjects with an aim to support acceleration of the vaccine candidate’s pediatric program   VLA15 will be  tested at two different schedules (Month 0-2-6 or Month 0-6) receiving the selected dose of 180µg VLA15 is the only Lyme disease vaccine candidate in active clinical development Saint-Herblain (France) and New York, NY, March 8, 2021 – Valneva SE (“Valneva”), a specialty vaccine company focused on prevention of diseases with major unmet needs, and Pfizer Inc. (NYSE: PFE) today announced initiation of study VLA15-221. The VLA15-221 study builds on previous positive Phase 2 studies, incorporates new dose regimens and is anticipated to be the final Phase 2 study readout before a decision to progress int

United statesNew yorkKathrin jansenBryan dunnJuan carlos jaramilloJerica pittsUs centers for diseaseDrug administrationExchange commissionPfizer incHead of pfizer vaccine researchInvestor relations corporate communicationsSenior vice presidentPfizer vaccine researchCarlos jaramilloChief medical officer